Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P05787: Variant p.Ser417Gly

Keratin, type II cytoskeletal 8
Gene: KRT8
Feedback?
Variant information Variant position: help 417 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Serine (S) to Glycine (G) at position 417 (S417G, p.Ser417Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page



Sequence information Variant position: help 417 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 483 The length of the canonical sequence.
Location on the sequence: help GEESRLESGMQNMSIHTKTT S GYAGGLSSAYGGLTSPGLSY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         GEESRLESGMQNMSIHTKTTS----GY----AGGLSSAYGGLTSPGLSY

Mouse                         GEESRLESGMQNMSIHTKTTS----GY----SGGLSSSYGG

Rat                           GEESRLESGMQNMSIHTKTTS----GY----AGGLSSSYGG

Bovine                        GEESRLESGMQNMSIHTKTTS----GY----AGGLTSSYG-

Xenopus laevis                GEESRLESGFQNLSIQTKTVSGVSSGF----GGGISSGFSN

Zebrafish                     GEEDRLATGIKAINISKQSTS--YGGYPMESAGSSYSTYSS

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 483 Keratin, type II cytoskeletal 8
Region 399 – 483 Tail
Modified residue 400 – 400 Phosphoserine
Modified residue 404 – 404 Phosphoserine
Modified residue 410 – 410 Phosphoserine
Modified residue 417 – 417 Phosphoserine
Modified residue 424 – 424 Phosphoserine
Modified residue 432 – 432 Phosphoserine; by CaMK2 and MAPK



Literature citations
Organization and sequence of the human gene encoding cytokeratin 8.
Krauss S.; Franke W.W.;
Gene 86:241-249(1990)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT GLY-417; Cytokeratin expression in simple epithelia. III. Detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by hybridization with cDNA sequences in vitro and in situ.
Leube R.E.; Bosch F.X.; Romano V.; Zimbelmann R.; Hofler H.; Franke W.W.;
Differentiation 33:69-85(1986)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 205-483 (ISOFORM 1); VARIANTS GLY-417 AND ASP-429;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.